PMID- 22654714
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20120823
LR  - 20211021
IS  - 1875-6190 (Electronic)
IS  - 1570-159X (Print)
IS  - 1570-159X (Linking)
VI  - 9
IP  - 4
DP  - 2011 Dec
TI  - Neurotrophins role in depression neurobiology: a review of basic and clinical 
      evidence.
PG  - 530-52
LID - 10.2174/157015911798376262 [doi]
AB  - Depression is a neuropsychiatric disorder affecting a huge percentage of the 
      active population especially in developed countries. Research has devoted much of 
      its attention to this problematic and many drugs have been developed and are 
      currently prescribed to treat this pathology. Yet, many patients are refractory 
      to the available therapeutic drugs, which mainly act by increasing the levels of 
      the monoamines serotonin and noradrenaline in the synaptic cleft. Even in the 
      cases antidepressants are effective, it is usually observed a delay of a few 
      weeks between the onset of treatment and remission of the clinical symptoms. 
      Additionally, many of these patients who show remission with antidepressant 
      therapy present a relapse of depression upon treatment cessation. Thus research 
      has focused on other possible molecular targets, besides monoamines, underlying 
      depression. Both basic and clinical evidence indicates that depression is 
      associated with several structural and neurochemical changes where the levels of 
      neurotrophins, particularly of brain-derived neurotrophic factor (BDNF), are 
      altered. Antidepressants, as well as other therapeutic strategies, seem to 
      restore these levels. Neuronal atrophy, mostly detected in limbic structures that 
      regulate mood and cognition, like the hippocampus, is observed in depressed 
      patients and in animal behavioural paradigms for depression. Moreover, chronic 
      antidepressant treatment enhances adult hippocampal neurogenesis, supporting the 
      notion that this event underlies antidepressants effects. Here we review some of 
      the preclinical and clinical studies, aimed at disclosing the role of 
      neurotrophins in the pathophysiological mechanisms of depression and the mode of 
      action of antidepressants, which favour the neurotrophic/neurogenic hypothesis.
FAU - Neto, Fani L
AU  - Neto FL
AD  - Instituto de Histologia e Embriologia, Faculdade de Medicina e IBMC, Universidade 
      do Porto, 4200-319, Porto, Portugal.
FAU - Borges, Gisela
AU  - Borges G
FAU - Torres-Sanchez, Sonia
AU  - Torres-Sanchez S
FAU - Mico, Juan A
AU  - Mico JA
FAU - Berrocoso, Esther
AU  - Berrocoso E
LA  - eng
PT  - Journal Article
PL  - United Arab Emirates
TA  - Curr Neuropharmacol
JT  - Current neuropharmacology
JID - 101157239
PMC - PMC3263450
OTO - NOTNLM
OT  - Antidepressants
OT  - BDNF
OT  - VGF.
OT  - Val66Met polymorphism
OT  - depression
OT  - hippocampal neurogenesis
OT  - neuropsychiatric disorders
OT  - stress
EDAT- 2012/06/02 06:00
MHDA- 2012/06/02 06:01
PMCR- 2012/06/01
CRDT- 2012/06/02 06:00
PHST- 2010/07/18 00:00 [received]
PHST- 2010/08/18 00:00 [revised]
PHST- 2010/08/09 00:00 [accepted]
PHST- 2012/06/02 06:00 [entrez]
PHST- 2012/06/02 06:00 [pubmed]
PHST- 2012/06/02 06:01 [medline]
PHST- 2012/06/01 00:00 [pmc-release]
AID - CN-9-530 [pii]
AID - 10.2174/157015911798376262 [doi]
PST - ppublish
SO  - Curr Neuropharmacol. 2011 Dec;9(4):530-52. doi: 10.2174/157015911798376262.